Clinical Trial Update: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of ledipasvir/sofosbuvir fixed-dose combination for 12 or 24 weeks in kidney transplant recipients with chronic HCV…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ledipasvir/sofosbuvir (Ledipasvir and sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2017-11-17